MedTrace Logo

Study to Assess the Efficacy and Safety of Favipiravir-HU

NCT04940871 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2022-11-09

No results posted yet for this study

Summary

The aim of the study is to assess the safety and efficacy of Favipiravir HU when administered to SARS-Cov- 2 patients in order to offer a safe and effective treatment to SARS-Cov-2 infection during the pandemic. The study is not for registration purposes and is not part of a series of studies for registration of Favipiravir HU.

Conditions

  • Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Interventions

DRUG

Favipiravir HU 200 mg hard capsules

Drug substance: Favipiravir Dose: 200 mg Administration: oral Formulation: capsules

DRUG

Placebo HU

Name: Placebo clinical sample Drug substance: placebo Dose: - Administration: oral Formulation: capsules

Sponsors & Collaborators

  • Hungarian Ministry of Innovation and Technology

    collaborator UNKNOWN

  • University of Pecs

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-25
Primary Completion
2021-11-29
Completion
2021-11-29

Countries

  • Hungary

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04940871 on ClinicalTrials.gov